xjb-5-131 and Huntington-Disease

xjb-5-131 has been researched along with Huntington-Disease* in 8 studies

Reviews

1 review(s) available for xjb-5-131 and Huntington-Disease

ArticleYear
A Double-Pronged Sword: XJB-5-131 Is a Suppressor of Somatic Instability and Toxicity in Huntington's Disease.
    Journal of Huntington's disease, 2022, Volume: 11, Issue:1

    Due to large increases in the elderly populations across the world, age-related diseases are expected to expand dramatically in the coming years. Among these, neurodegenerative diseases will be among the most devastating in terms of their emotional and economic impact on patients, their families, and associated subsidized health costs. There is no currently available cure or rescue for dying brain cells. Viable therapeutics for any of these disorders would be a breakthrough and provide relief for the large number of affected patients and their families. Neurodegeneration is accompanied by elevated oxidative damage and inflammation. While natural antioxidants have largely failed in clinical trials, preclinical phenotyping of the unnatural, mitochondrial targeted nitroxide, XJB-5-131, bodes well for further translational development in advanced animal models or in humans. Here we consider the usefulness of synthetic antioxidants for the treatment of Huntington's disease. The mitochondrial targeting properties of XJB-5-131 have great promise. It is both an electron scavenger and an antioxidant, reducing both somatic expansion and toxicity simultaneously through the same redox mechanism. By quenching reactive oxygen species, XJB-5-131 breaks the cycle between the rise in oxidative damage during disease progression and the somatic growth of the CAG repeat which depends on oxidation.

    Topics: Aged; Animals; Antioxidants; Cyclic N-Oxides; Humans; Huntington Disease; Oxidative Stress

2022

Other Studies

7 other study(ies) available for xjb-5-131 and Huntington-Disease

ArticleYear
XJB-5-131 Is a Mild Uncoupler of Oxidative Phosphorylation.
    Journal of Huntington's disease, 2022, Volume: 11, Issue:2

    Mitochondria (MT) are energy "powerhouses" of the cell and the decline in their function from oxidative damage is strongly correlated in many diseases. To suppress oxygen damage, we have developed and applied XJB-5-131 as a targeted platform for neutralizing reactive oxygen species (ROS) directly in MT. Although the beneficial activity of XJB-5-131 is well documented, the mechanism of its protective effects is not yet fully understood.. Here, we elucidate the mechanism of protection for XJB-5-131, a mitochondrial targeted antioxidant and electron scavenger.. The Seahorse Flux Analyzer was used to probe the respiratory states of isolated mouse brain mitochondria treated with XJB-5-131 compared to controls.. Surprisingly, there is no direct impact of XJB-5-131 radical scavenger on the electron flow through the electron transport chain. Rather, XJB-5-131 is a mild uncoupler of oxidative phosphorylation. The nitroxide moiety in XJB-5-131 acts as a superoxide dismutase mimic, which both extracts or donates electrons during redox reactions. The electron scavenging activity of XJB-5-131 prevents the leakage of electrons and reduces formation of superoxide anion, thereby reducing ROS.. We show here that XJB-5-131 is a mild uncoupler of oxidative phosphorylation in MT. The mild uncoupling property of XJB-5-131 arises from its redox properties, which exert a protective effect by reducing ROS-induced damage without sacrificing energy production. Because mitochondrial decline is a common and central feature of toxicity, the favorable properties of XJB-5-131 are likely to be useful in treating Huntington's disease and a wide spectrum of neurodegenerative diseases for which oxidative damage is a key component. The mild uncoupling properties of XJB-5-131 suggest a valuable mechanism of action for the design of clinically effective antioxidants.

    Topics: Animals; Cyclic N-Oxides; Huntington Disease; Mice; Oxidative Phosphorylation; Oxidative Stress; Reactive Oxygen Species

2022
XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.
    PloS one, 2018, Volume: 13, Issue:4

    We have reported that the radical scavenger XJB-5-131 attenuates or reverses progression of the disease phenotype in the HdhQ(150/150) mouse, a slow onset model of HD. Here, we tested whether XJB-5-131 has beneficial effects in R6/2 mice, a severe early onset model of HD. We found that XJB-5-131 has beneficial effects in R6/2 mice, by delaying features of the motor and histological phenotype. The impact was sex-dependent, with a stronger effect in male mice. XJB-5-131 treatment improved some locomotor deficits in female R6/2 mice, but the effects were, in general, greater in male mice. Chronic treatment of male R6/2 mice with XJB-5-1-131 reduced weight loss, and improved the motor and temperature regulation deficits, especially in male mice. Treatment with XJB-5-131 had no effect on the lifespan of R6/2 mice. Nevertheless, it significantly slowed somatic expansion at 90 days, and reduced the density of inclusions. Our data show that while treatment with XJB-5-131 had complex effects on the phenotype of R6/2 mice, it produced a number of significant improvements in this severe model of HD.

    Topics: Age Factors; Animals; Behavior, Animal; Body Temperature; Cyclic N-Oxides; Disease Progression; Female; Huntington Disease; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Motor Activity; Phenotype; Sex Factors

2018
Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.
    Human molecular genetics, 2016, 05-01, Volume: 25, Issue:9

    Oxidative damage to mitochondria (MT) is a major mechanism for aging and neurodegeneration. We have developed a novel synthetic antioxidant, XJB-5-131, which directly targets MT, the primary site and primary target of oxidative damage. XJB-5-131 prevents the onset of motor decline in an HdhQ(150/150) mouse model for Huntington's disease (HD) if treatment starts early. Here, we report that XJB-5-131 attenuates or reverses disease progression if treatment occurs after disease onset. In animals with well-developed pathology, XJB-5-131 promotes weight gain, prevents neuronal death, reduces oxidative damage in neurons, suppresses the decline of motor performance or improves it, and reduces a graying phenotype in treated HdhQ(150/150) animals relative to matched littermate controls. XJB-5-131 holds promise as a clinical candidate for the treatment of HD.

    Topics: Animals; Behavior, Animal; Cells, Cultured; Cyclic N-Oxides; Disease Models, Animal; Huntington Disease; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; Neurons; Oxidative Stress; Weight Loss

2016
Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease.
    PLoS genetics, 2015, Volume: 11, Issue:8

    Huntington's Disease (HD) is caused by inheritance of a single disease-length allele harboring an expanded CAG repeat, which continues to expand in somatic tissues with age. The inherited disease allele expresses a toxic protein, and whether further somatic expansion adds to toxicity is unknown. We have created an HD mouse model that resolves the effects of the inherited and somatic expansions. We show here that suppressing somatic expansion substantially delays the onset of disease in littermates that inherit the same disease-length allele. Furthermore, a pharmacological inhibitor, XJB-5-131, inhibits the lengthening of the repeat tracks, and correlates with rescue of motor decline in these animals. The results provide evidence that pharmacological approaches to offset disease progression are possible.

    Topics: Animals; Cyclic N-Oxides; Disease Models, Animal; Disease Progression; DNA Glycosylases; Female; Huntington Disease; Male; Mice, Inbred C57BL; Mice, Knockout; Trinucleotide Repeat Expansion

2015
Putting the Brakes on Huntington Disease in a Mouse Experimental Model.
    PLoS genetics, 2015, Volume: 11, Issue:8

    Topics: Animals; Cyclic N-Oxides; Female; Huntington Disease; Male; Trinucleotide Repeat Expansion

2015
Promising compound targets mitochondria in Huntington's disease.
    Future medicinal chemistry, 2013, Volume: 5, Issue:1

    Topics: Animals; Cyclic N-Oxides; Humans; Huntington Disease; Mice; Mitochondria

2013
Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.
    Cell reports, 2012, Nov-29, Volume: 2, Issue:5

    Oxidative damage and mitochondrial dysfunction are implicated in aging and age-related neurodegenerative diseases, including Huntington's disease (HD). Many naturally occurring antioxidants have been tested for their ability to correct for deleterious effects of reactive oxygen species, but often they lack specificity, are tissue variable, and have marginal efficacy in human clinical trials. To increase specificity and efficacy, we have designed a synthetic antioxidant, XJB-5-131, to target mitochondria. We demonstrate in a mouse model of HD that XJB-5-131 has remarkably beneficial effects. XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function. The findings poise XJB-5-131 as a promising therapeutic compound.

    Topics: Animals; Antioxidants; Cell Survival; Cells, Cultured; Cyclic N-Oxides; Disease Models, Animal; DNA Damage; DNA, Mitochondrial; Gene Dosage; Huntington Disease; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; Neurons; Oxidative Stress; Weight Loss

2012